Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Five-year evaluation of bone health in liver transplant patients: developing a risk score for predicting bone fragility progression beyond the first year.

Frontiers in endocrinology·2025
Same author

Systemic Osteoporosis and Osteopenia Among Periprosthetic Fractures After Total Hip Arthroplasty.

The Journal of arthroplasty·2024
Same author

Improving Handoffs After Osteoporotic Fractures.

Journal of the American Medical Directors Association·2023
Same author

Managing Bone Health in Breast Cancer.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2022
Same author

Coronary artery calcium and bone mineral density by serial CTA: Does menopausal hormone therapy modify the association?

Clinical imaging·2022
Same author

Survival in primary hyperparathyroidism over five decades (1965-2010) a population-based retrospective study.

Bone·2021

Related Experiment Videos

Update on medications with adverse skeletal effects.

Caroline J Davidge Pitts1, Ann E Kearns

  • 1Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA.

Mayo Clinic Proceedings
|March 11, 2011
PubMed
Summary

Primary care physicians must monitor medications with potential bone health risks. This review covers new "bad to the bone" drugs and managing glucocorticoid-induced osteoporosis.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Bone Health

Background:

  • Primary care physicians manage complex patient conditions requiring multiple medications.
  • Balancing treatment risks and benefits is challenging due to evolving drug information.
  • An increasing number of medications are associated with adverse skeletal health effects.

Purpose of the Study:

  • To review recently identified medications with potential adverse skeletal effects.
  • To discuss advances in managing glucocorticoid-induced osteoporosis.
  • To provide a practical framework for assessing and managing skeletal risks associated with medications.

Main Methods:

  • Literature review of recent studies on drug-induced bone toxicity.
  • Analysis of emerging data on medication risks to skeletal health.

Related Experiment Videos

  • Synthesis of current management strategies for glucocorticoid-induced osteoporosis.

    • Main Results:

    • Several new medications have been identified as potentially harmful to bone health.
    • Recent advancements offer improved management options for glucocorticoid-induced osteoporosis.
    • A practical approach to risk assessment and management is presented.

    Conclusions:

    • Physicians need to be aware of medications negatively impacting bone health.
    • Effective management strategies exist for glucocorticoid-induced osteoporosis.
    • Proactive assessment and management of skeletal risks are crucial in primary care.